Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 8, 2015, Pages 1245-1253

  Zhang, Hongjie ^a   Garcia, Jose M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anamorelin; Cancer anorexia cachexia syndrome; Ghrelin; NSCLC

Indexed keywords

ANAMORELIN; GHRELIN; GHRELIN RECEPTOR; HYDRAZINE DERIVATIVE; OLIGOPEPTIDE;

A WAVE; ANOREXIA; CACHEXIA; CANCER ANOREXIA CACHEXIA SYNDROME; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERGLYCEMIA; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH DISCOMFORT; AGONISTS; ANIMAL; APPETITE; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM;

ANIMALS; ANOREXIA; APPETITE; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; HYDRAZINES; LUNG NEOPLASMS; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GHRELIN;

EID: 84929157466     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1041500     Document Type: Review

References (73)

1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12(5):489-95
2. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12(7):1193-201
3. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1(1):1-5
4. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69(4):491-7
5. Kumar NB, Kazi A, Smith T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010;11(3-4):107-17
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
8. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91(4):1133S-7S
9. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31(12):1539-47
10. Roberts BM, Ahn B, Smuder AJ, et al. Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J 2013;27(7):2600-10
11. Laviano A, Koverech A, Mari A. Cachexia: clinical features when inflammation drives malnutrition. Proc Nutr Soc 2015;1-7
12. Argiles JM, Stemmler B. The potential of ghrelin in the treatment of cancer cachexia. Expert Opin Biol Ther 2013;13(1):67-76
13. European Palliative Care Research Collaborative. European Clinical Guidelines: Clincal practice guidelines on cancer cachexia in advancer cancer patients with a focus on refractory cachexia. 2010
14. Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011;2011:601434
15. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nature reviews Clinical oncology 2013;10(2):90-9
16. Bozzetti F, Gavazzi C, Mariani L, Crippa F. Artificial nutrition in cancer patients: which route, what composition? World J Surg 1999;23(6):577-83
17. Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993;11(10):2043-9
18. Lundholm K, Korner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007;13(9):2699-706
19. Del Fabbro E, Dev R, Hui D, et al. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a doubleblind placebo-controlled trial. J Clin Oncol 2013;31(10):1271-6
20. Murphy RA, Yeung E, Mazurak VC, Mourtzakis M. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 2011;105(10):1469-73
21. Gorter RW. [Experiences with dronabinol (delta-tetrahydrocannabinol) in oncological patients with anorexiacachexia syndrome. Illustration of clinical problems and therapy based on 2 case reports]. Schmerz 2004;18(Suppl 2):S31-3
22. Tazi E, Errihani H. Treatment of cachexia in oncology. Indian J Palliat Care 2010;16(3):129-37
23. Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancerrelated anorexia-cachexia symptoms: results of a double-blind placebocontrolled randomized study. J Palliat Med 2012;15(10):1059-64
24. Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14(4):335-45
25. Crawford J, Dalton JT, Hancock ML. Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC. Eur J Cancer 2013;49(Suppl 2):LBA21
26. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402(6762):656-60
27. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol 2004;25(1):27-68
28. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85(2):495-522
29. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004;25(3):426-57
30. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85(12):4908-11
31. Jerlhag E. Systemic administration of ghrelin induces conditioned place preference and stimulates accumbal dopamine. Addict Biol 2008;13(3-4):358-63
32. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003;37(4):649-61
33. Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, et al. Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats. Regul Pept 2010;160(1-3):81-90
34. Garcia JM, Scherer T, Chen JA, et al. Inhibition of Cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology 2013;154(9):3118-29
35. Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29(12):1527-34
36. Van der Ploeg L, Laken H, Sharma S, et al. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci 2014;109(1):20-9
37. Akamizu T, Kangawa K. Ghrelin for cachexia. J Cachexia Sarcopenia Muscle 2010;1(2):169-76
38. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin-and activationinduced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004;114(1):57-66
39. Chen J, Splenser A, Guillory B, et al. Ghrelin prevents tumor-and cisplatininduced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sacropenia Muscle 2015; In press
40. Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004;109(18):2221-6
41. Chapman IM, Pescovitz OH, Murphy G, et al. Oral administration of growth hormone (GH) releasing peptidemimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J Clin Endocrinol Metab 1997;82(10):3455-63
42. Guan XM, Yu H, Palyha OC, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 1997;48(1):23-9
43. Zigman JM, Jones JE, Lee CE, et al. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol 2006;494(3):528-48
44. Mondal MS, Date Y, Yamaguchi H, et al. Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Regul Pept 2005;126(1-2):55-9
45. Willesen MG, Kristensen P, Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999;70(5):306-16
46. Yada T, Damdindorj B, Rita RS, et al. Ghrelin signalling in beta-cells regulates insulin secretion and blood glucose. Diabetes obesity Metabol 2014;16(Suppl 1):111-17
47. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002;87(6):2988
48. Sun Y, Butte NF, Garcia JM, Smith RG. Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology 2008;149(2):843-50
49. Kitahara A, Takahashi K, Moriya R, et al. Ghrelin augments the expressions and secretions of proinflammatory adipokines, VEGF120 and MCP-1, in differentiated 3T3-L1 adipocytes. J Cell Physiol 2015;230(1):199-209
50. Porporato PE, Filigheddu N, Reano S, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 2013;123(2):611-22
51. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89(6):2832-6
52. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebocontrolled, double-blind, doublecrossover study. Br J Cancer 2008;98(2):300-8
53. Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 2012;118(19):4785-94
54. Lundholm K, Gunnebo L, Korner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized doubleblind study. Cancer 2010;116(8):2044-52
55. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebocontrolled, multiple-dose study in healthy volunteers. Oncologist 2007;12(5):594-600
56. Khan AS, Smith LC, Anscombe IW, et al. Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice. Cancer Gene Ther 2005;12(1):54-60
57. Kim HJ, Kim HJ, Yun J, et al. Pathophysiological role of hormones and cytokines in cancer cachexia. J Korean Med Sci 2012;27(2):128-34
58. Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle 2014;5(4):329-37
59. Leese PT, Trang JM, Blum RA, Groot E. An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin. Clin Pharm Drug Dev 2015;4(2):112-20
60. Kumor K, Polvino W. Biologic activity of RC-1291, a novel oral ghrelin mimetic for cancer anorexia/cachexia: results from a phase I randomized, double-blind, placebo-controlled trial in healthy volunteer. Supportive care cancer 2006;14:583-687
61. Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 2009;19(3):267-73
62. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013;21(1):129-37
63. Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 2015;16(1):108-16
64. Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 2014;15
65. Temel J, Bondarde S, Jain M, et al. Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebocontrolled, multicenter Phase II study. European Cancer Congress Amsterdam, The Netherlands 1308, 2013. Available from: wwwpostersubmissioncom/ board/ [Last accessed on 14 November 2013]
66. Temel JS, Bondarde SA, Jain MM, et al. Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. J Clin Oncol 2013;31:Suppl 31; abstr 42
67. Bonomi P, Temel J, Currow D, et al. Anamorelin for the Treatment of Cancer Anorexia-Cachexia in Advanced NSCLC Patients: Results From ROMANA 1, a Pivotal Phase 3 Study. Int J Radiat Oncol Biol Phys 2014;90(5S Suppl):abstract 5
68. Abernethy AP, Currow D, Fearon K, et al. Anamorelin for the treatment of cancer anorexia-cachexia: Baseline characteristics from three phase III clinical trials (the ROMANA program). J Clin Oncol 2014;32(Suppl):abstract e20694
69. Temel J, Currow D, Fearon K, et al. Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: Results from the phase 3 studies ROMANA 1 and 2. Ann Oncol 2014;25(5):1-41
70. Heppner KM, Tong J. Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur J Endocrinol 2014;171(1):R21-32
71. Northrup R, Kuroda K, Duus EM, et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer 2013;21(9):2409-15
72. Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 2012;3(4):245-51
73. Fujitsuka N, Uezono Y. Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Frontiers in pharmacology 2014;5:271